AXSM

Axsome Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat

90%

bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression

60%

bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action

80%

neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure

50%

Filing History

10-QMay 4, 2026

The Q1 2026 filing presents a classic biotech trade-off: impressive top-line commercial acceleration versus precarious operational leverage. Axsome has proven it can sell its products and win regulatory approvals, but it has yet to prove it can do so without burning through its cash reserves. The shift in the investment narrative now centers on whether the Alzheimer's agitation label for AUVELITY can provide the necessary scale to offset the massive SG&A spend and debt obligations. Investors must weigh the ability of the company to maintain its patent shields against the reality of its debt structure and insider behavior. While the revenue trajectory is undeniably bullish, the underlying financial architecture is fragile, making the company highly sensitive to any miss in sales targets or an adverse legal ruling. The path to cash flow positivity is clear, but the margin for error is dangerously slim.